Raises FY26 Revenue Outlook to $1.46B-$1.5B
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 06 2026
0mins
Consensus $3.03. Raises FY26 revenue view to $1.46B-$1.5B from $1.45B-$1.5B, consensus $1.49B.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PAHC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PAHC
Wall Street analysts forecast PAHC stock price to rise
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 30.840
Low
45.00
Averages
47.50
High
50.00
Current: 30.840
Low
45.00
Averages
47.50
High
50.00
About PAHC
Phibro Animal Health Corporation is a diversified developer, manufacturer and marketer of a range of animal health and mineral nutrition products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture and dogs. The Company is also a manufacturer and marketer of performance products for use in the personal care, industrial chemical and chemical catalyst industries. Its segments include Animal Health, Mineral Nutrition and Performance Products. The Animal Health segment develops, manufactures and markets antibacterials which inhibit the growth of pathogenic bacteria that cause infections in animals. The Mineral Nutrition segment manufactures and markets formulations and concentrations of trace minerals such as zinc, manganese, copper, iron and other compounds. The Performance Products segment manufactures and markets specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bruker Corporation Shares Surge 50.3% Amid Strong Growth
- Outstanding Stock Performance: Bruker Corporation's shares have surged 50.3% over the past year, significantly outperforming the industry growth of 42.5%, reflecting the company's strong performance in life sciences and materials research, which boosts investor confidence.
- Growth Drivers: The BSI NANO segment reported organic bookings growth exceeding expectations, driving performance in Q1 2026, with a book-to-bill ratio above 1.0 for the third consecutive quarter, indicating robust market demand.
- Financial Health: As of Q1 2026, the company reported cash and cash equivalents of $133.4 million, down from $298.8 million at the end of 2025, but reduced long-term debt by $181.3 million, lowering net leverage to 2.9X, demonstrating financial stability.
- Competitive Challenges: While the company has gained market share in the preclinical imaging space, it faces pressure from larger competitors, particularly in a softer demand environment for academic and industrial customers, which may impact future growth potential.
See More
Phibro Animal Health Director Acquires Shares Amid Market Challenges
- Share Acquisition Details: E. Thomas Corcoran, Director of Phibro Animal Health, acquired 10,000 shares at a weighted average price of $31.77 on May 29, 2026, totaling approximately $318,000, indicating his bullish outlook on the company's future despite market challenges.
- Ownership Increase: Following this transaction, Corcoran's direct holdings rose to 41,459 shares, a 31.79% increase, which enhances his capacity for future acquisitions, although the market's reaction to the company remains tepid.
- Market Reaction Analysis: While Corcoran's purchase suggests optimism about the company's prospects, Phibro's stock has dropped about 47% since April, primarily due to Brazil's ban on certain antibiotic feed additives, reflecting market concerns about the company's future performance.
- Financial Performance Overview: In the fiscal third quarter of 2026, Phibro reported a 10% year-over-year increase in net sales to $383.5 million, and despite anticipated declines in antibiotic feed additive sales in Brazil, the company expects net sales to range between $1.46 billion and $1.5 billion for fiscal 2026, demonstrating resilience in the market.
See More
Corcoran Increases Phibro Stock Holdings by 31.79%
- Share Acquisition Details: E. Thomas Corcoran purchased 10,000 shares of Phibro Animal Health on May 29, 2026, at a weighted average price of $31.77 per share, totaling approximately $318,000, which increased his direct ownership by 31.79%, bringing his total holdings to 41,459 shares.
- Market Reaction Analysis: Despite Corcoran's purchase indicating a bullish outlook for the company, Phibro's stock has dropped about 47% since April, primarily due to Brazil's prohibition on certain antibiotic feed additives, which has negatively impacted market sentiment.
- Financial Performance Overview: For the fiscal third quarter ending March 31, 2026, Phibro reported a 10% year-over-year increase in net sales to $383.5 million; however, the company anticipates a downturn in antibiotic feed additive sales in Brazil, projecting net sales for fiscal 2026 to be between $1.46 billion and $1.5 billion.
- Industry Outlook: Phibro is launching a digital platform in the Brazilian market to facilitate the veterinary prescription process, and despite regulatory challenges, the company maintains a competitive position in the animal health industry through its diversified product portfolio and established distribution channels, indicating long-term growth potential.
See More
Phibro Animal Health Corporation Earnings Analysis
- Core Business Growth: Phibro Animal Health Corporation reported adjusted earnings per share of $0.76 for fiscal Q3 2026, an 18.75% increase from $0.64 in the prior year, exceeding market expectations by 5.92%, indicating strong execution in its core Animal Health segment.
- Strong Revenue Performance: The company achieved a 10.3% year-over-year revenue growth to $383.5 million in Q3, surpassing consensus by 6.26%, with net sales in the Animal Health segment rising 13% to $291.2 million, driven by robust demand for medicated feed additives and vaccines.
- Margin Improvement: Despite a 6% increase in cost of goods sold, gross profit rose 20.2% year-over-year to $125.6 million, with gross margin expanding by 271 basis points to 32.8%, reflecting improvements in product mix and operational execution that helped offset cost pressures.
- Optimistic Future Outlook: Management updated fiscal 2026 guidance, expecting net sales in the range of $1.46 to $1.50 billion, implying 14% growth, and adjusted earnings per share projected between $2.98 and $3.10, representing a 45% improvement over fiscal 2025, showcasing confidence in continued Animal Health execution.
See More
Phibro (PAHC) Q3 2026 Earnings Transcript
See More
Phibro Animal Health CEO Sells Shares Amid Transition
- Share Reduction Details: Jack Bendheim, CEO of Phibro Animal Health, indirectly sold 18,608 shares of common stock between May 5 and May 7, 2026, totaling approximately $1 million, which reduced his indirect holdings from 74,760 to 56,152 shares, indicating a potential decrease in confidence regarding the company's future.
- Trading Plan Context: This sale was executed under a Rule 10b5-1 trading plan established on December 11, 2025, reflecting Bendheim's strategic adjustment ahead of his transition from CEO to Executive Chairman, suggesting a cautious approach during the governance change.
- Ownership Analysis: Despite the sale, Bendheim retains 16,840 direct shares and 56,152 indirect shares, totaling 449,485 Class A common stock shares convertible into common stock, indicating he still maintains significant economic interest and influence within the company.
- Company Performance Overview: Phibro Animal Health reported a revenue of $1.5 billion and a net income of $95.23 million, with a dividend yield of 1.88% and a 50.21% increase in stock price over the past year, highlighting the company's strong performance and growth potential in the animal health product market.
See More
Bruker Corporation Shares Surge 50.3% Amid Strong Growth
- Outstanding Stock Performance: Bruker Corporation's shares have surged 50.3% over the past year, significantly outperforming the industry growth of 42.5%, reflecting the company's strong performance in life sciences and materials research, which boosts investor confidence.
- Growth Drivers: The BSI NANO segment reported organic bookings growth exceeding expectations, driving performance in Q1 2026, with a book-to-bill ratio above 1.0 for the third consecutive quarter, indicating robust market demand.
- Financial Health: As of Q1 2026, the company reported cash and cash equivalents of $133.4 million, down from $298.8 million at the end of 2025, but reduced long-term debt by $181.3 million, lowering net leverage to 2.9X, demonstrating financial stability.
- Competitive Challenges: While the company has gained market share in the preclinical imaging space, it faces pressure from larger competitors, particularly in a softer demand environment for academic and industrial customers, which may impact future growth potential.
See More
Phibro Animal Health Director Acquires Shares Amid Market Challenges
- Share Acquisition Details: E. Thomas Corcoran, Director of Phibro Animal Health, acquired 10,000 shares at a weighted average price of $31.77 on May 29, 2026, totaling approximately $318,000, indicating his bullish outlook on the company's future despite market challenges.
- Ownership Increase: Following this transaction, Corcoran's direct holdings rose to 41,459 shares, a 31.79% increase, which enhances his capacity for future acquisitions, although the market's reaction to the company remains tepid.
- Market Reaction Analysis: While Corcoran's purchase suggests optimism about the company's prospects, Phibro's stock has dropped about 47% since April, primarily due to Brazil's ban on certain antibiotic feed additives, reflecting market concerns about the company's future performance.
- Financial Performance Overview: In the fiscal third quarter of 2026, Phibro reported a 10% year-over-year increase in net sales to $383.5 million, and despite anticipated declines in antibiotic feed additive sales in Brazil, the company expects net sales to range between $1.46 billion and $1.5 billion for fiscal 2026, demonstrating resilience in the market.
See More
Corcoran Increases Phibro Stock Holdings by 31.79%
- Share Acquisition Details: E. Thomas Corcoran purchased 10,000 shares of Phibro Animal Health on May 29, 2026, at a weighted average price of $31.77 per share, totaling approximately $318,000, which increased his direct ownership by 31.79%, bringing his total holdings to 41,459 shares.
- Market Reaction Analysis: Despite Corcoran's purchase indicating a bullish outlook for the company, Phibro's stock has dropped about 47% since April, primarily due to Brazil's prohibition on certain antibiotic feed additives, which has negatively impacted market sentiment.
- Financial Performance Overview: For the fiscal third quarter ending March 31, 2026, Phibro reported a 10% year-over-year increase in net sales to $383.5 million; however, the company anticipates a downturn in antibiotic feed additive sales in Brazil, projecting net sales for fiscal 2026 to be between $1.46 billion and $1.5 billion.
- Industry Outlook: Phibro is launching a digital platform in the Brazilian market to facilitate the veterinary prescription process, and despite regulatory challenges, the company maintains a competitive position in the animal health industry through its diversified product portfolio and established distribution channels, indicating long-term growth potential.
See More
Phibro Animal Health Corporation Earnings Analysis
- Core Business Growth: Phibro Animal Health Corporation reported adjusted earnings per share of $0.76 for fiscal Q3 2026, an 18.75% increase from $0.64 in the prior year, exceeding market expectations by 5.92%, indicating strong execution in its core Animal Health segment.
- Strong Revenue Performance: The company achieved a 10.3% year-over-year revenue growth to $383.5 million in Q3, surpassing consensus by 6.26%, with net sales in the Animal Health segment rising 13% to $291.2 million, driven by robust demand for medicated feed additives and vaccines.
- Margin Improvement: Despite a 6% increase in cost of goods sold, gross profit rose 20.2% year-over-year to $125.6 million, with gross margin expanding by 271 basis points to 32.8%, reflecting improvements in product mix and operational execution that helped offset cost pressures.
- Optimistic Future Outlook: Management updated fiscal 2026 guidance, expecting net sales in the range of $1.46 to $1.50 billion, implying 14% growth, and adjusted earnings per share projected between $2.98 and $3.10, representing a 45% improvement over fiscal 2025, showcasing confidence in continued Animal Health execution.
See More
Phibro (PAHC) Q3 2026 Earnings Transcript
See More
Phibro Animal Health CEO Sells Shares Amid Transition
- Share Reduction Details: Jack Bendheim, CEO of Phibro Animal Health, indirectly sold 18,608 shares of common stock between May 5 and May 7, 2026, totaling approximately $1 million, which reduced his indirect holdings from 74,760 to 56,152 shares, indicating a potential decrease in confidence regarding the company's future.
- Trading Plan Context: This sale was executed under a Rule 10b5-1 trading plan established on December 11, 2025, reflecting Bendheim's strategic adjustment ahead of his transition from CEO to Executive Chairman, suggesting a cautious approach during the governance change.
- Ownership Analysis: Despite the sale, Bendheim retains 16,840 direct shares and 56,152 indirect shares, totaling 449,485 Class A common stock shares convertible into common stock, indicating he still maintains significant economic interest and influence within the company.
- Company Performance Overview: Phibro Animal Health reported a revenue of $1.5 billion and a net income of $95.23 million, with a dividend yield of 1.88% and a 50.21% increase in stock price over the past year, highlighting the company's strong performance and growth potential in the animal health product market.
See More
